Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment - 19/06/20

Funding sources: None. |
|
Conflicts of interest: Dr Gisondi served as consultant for AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Pierre Fabre, Sanofi, and UCB. Dr Girolomoni served as consultant for AbbVie, Abiogen, Almirall, Amgen, Bayer, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Hospira, LEO Pharma, Merck, MSD, Mundipharma, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Sanofi, and Sun Pharma. Drs Del Giglio, Rossi, Zaza, and Iacono have no conflicts of interest to declare. |
|
IRB approval status: The IRB was notified of the observational study. |
|
Reprints not available from the authors. |
Vol 83 - N° 1
P. 285-287 - juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.